Live Analyst Rating Changes 2848 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Luisa Hector
BER
Luisa Hector
Berenberg Bank
Wall Street Analyst
★★★☆☆
#1535
on 13Foresight · ranked by our own returns
57%
Success Rate
+8.4%
Average Return
4 of 7 calls profitable · -218.2% vs benchmark
📈 Across the calls we could measure, roughly 57% of Luisa Hector's ratings turned a profit when each position was held for 1 year — averaging +8.4% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

38 Buy 23 Hold 0 Sell
Luisa's Stock Coverage 16 ratings · 2026-06-25
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
MRK
Merck & Company
 Jun 22, 2026 HOLD Strong Buy
+5.1% avg upside
43 analysts
$125.00
4.50% Upside
 +8.9%
CH:ROP
Roche Holding AG
 May 08, 2026 HOLD Strong Buy
-0.3% avg upside
23 analysts
$340.00
4.64% Upside
 ·
ABBV
AbbVie
 May 08, 2026 BUY Buy
-5.0% avg upside
43 analysts
$275.00
17.21% Upside
 +19.3%
FR:SAN
Sanofi
 May 06, 2026 BUY Strong Buy
+34.2% avg upside
30 analysts
$105.00
42.89% Upside
 ·
GB:AZN
AstraZeneca
 Mar 16, 2026 BUY Strong Buy
+7.0% avg upside
26 analysts
$17000.00
25.19% Upside
 ·
CH:NOVN
Novartis AG
 Mar 06, 2026 HOLD Buy
-13.9% avg upside
31 analysts
$110.00
10.92% Downside
 ·
GB:BTRW
Barratt Redrow
 Feb 11, 2026 HOLD Strong Buy
+1257.4% avg upside
18 analysts
$414.00
57.08% Upside
 ·
GB:0QIU
Novo Nordisk
 Jan 16, 2026 BUY Hold
+33.5% avg upside
29 analysts
$415.00
34.92% Upside
 ·
GB:GSK
GlaxoSmithKline
 Jan 06, 2026 HOLD Hold
-4.3% avg upside
25 analysts
$1660.00
15.28% Downside
 ·
SNY
Sanofi
 May 16, 2025 BUY Strong Buy
+77.5% avg upside
20 analysts
$67.00
61.13% Upside
 -12.8%
BMY
Bristol-Myers Squibb
 Dec 10, 2024 HOLD Buy
+6.7% avg upside
42 analysts
$60.00
7.99% Upside
 -7.5%
SE:SOBI
Swedish Orphan Biovitrum AB
 Feb 28, 2024 BUY Strong Buy
-18.9% avg upside
6 analysts
 — ·
DE:MRK
Merck KGaA
 Feb 10, 2022 HOLD Buy
-2.3% avg upside
33 analysts
$197.00
45.99% Upside
 ·
PFE
Pfizer
 Jun 14, 2021 HOLD Buy
+39.4% avg upside
45 analysts
$43.00
73.85% Upside
 +25.0%
DE:BAYN
Bayer
 Sep 11, 2018 HOLD Strong Buy
+28.3% avg upside
28 analysts
$78.45
103.18% Upside
 ·
BAYRY
Bayer
 Sep 15, 2016 HOLD Buy
+266.6% avg upside
9 analysts
 — +31.4%
🔒 11 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Luisa Hector — Frequently Asked Questions
How accurate are Luisa Hector's stock ratings?
Based on the calls 13Foresight could measure, about 43% of Luisa's ratings were profitable over a one-year hold, with an average return of +6.5% per rating, or -220.2% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Luisa ranked on 13Foresight?
Luisa Hector is currently ranked #1535 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Luisa cover?
Luisa most recently has ratings on MRK, CH:ROP, ABBV, FR:SAN, GB:AZN, CH:NOVN, GB:BTRW, GB:0QIU, GB:GSK, SNY, BMY, SE:SOBI and 4 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.